ASRS President Reflects on a Year of Change
-
By
-
Geoffrey G. Emerson, MD, PhD, FASRS
-
July 15, 2026
-
3 min
By
Geoffrey G. Emerson, MD, PhD, FASRS
July 15, 2026
Several FDA decisions across multiple specialties are expected this month.
April 29, 2026
Although the trial missed its primary endpoint, exploratory analyses suggested slower lesion growth and better functional outcomes with gildeuretinol.
July 20, 2026
Fundus-based model showed moderate-to-good accuracy and improved performance when combined with clinical risk factors in a high-risk cohort
April 17, 2026